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Objective: Surgical portosystemic shunts are safe and effective for treating rebleeding gastric varices (GV)
in portal hypertensive patients with well-preserved liver function. The aim of this study is to investigate
the clinical outcomes of using selected surgical shunts for managing rebleeding GV at a single institution
in eastern Taiwan.
Materials and Methods: We retrospectively recruited 12 patients who received distal splenorenal shunts
(DSRS) following the indication of rebleeding GV or hypersplenism from January 2001 through December
2010. Their demographic data, etiology of portal hypertension, associated treatments, perioperative
complications and clinical outcomes were reviewed.
Results: All patients received DSRS, including 10 adults and two children, and were examined for
a median follow-up period of 53 months. No postoperative encephalopathy, major complications, or
surgical mortality occurred. Two of the patients were waiting for liver transplants. Late rebleeding in
esophageal varices developed in two patients who were successfully managed using endoscopic treat-
ment. The etiology of portal hypertension had no signiﬁcant impact on the postoperative complications.
Conclusion: Although there were a limited number of cases in this series, our results indicate that the
DSRS is an effective treatment for rebleeding GV, especially for patients with well-preserved liver
function and taking into account the realities of organ shortages.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
The management of patients with variceal bleeding that results
from portal hypertension can be divided into two steps: control of
acute bleeding episodes and prevention of recurrent variceal
hemorrhage. Surgical portosystemic shunts for portal decompres-
sion are generally applied to treat repeated episodes esoph-
agogastric variceal bleeding that is not amenable to medical or
endoscopic therapies. The concept of selective portosystemic
shunting is based on the principle that the selective deviation of
venous blood from the esophagogastrosplenic area to systemic
circulation keeps the mesoportal blood ﬂow intact. This concept
was developed in the 1960s by Warren et al [1]. The clinical results
of using the distal splenorenal shunt (DSRS), a favorable type ofBuddhist Tzu Chi General
n, Taiwan. Tel.: þ886 3856
. Lee).
ddhist Compassion Relief Tzu Chiselective portosystemic shunt, are almost universally reproducible,
and many centers have shown encouraging results [2e5]. Over the
past three decades, the roles of pharmacotherapy, endoscopic
therapy, transjugular intrahepatic portosystemic shunting (TIPSS),
and liver transplantation (LT) for treating patients with portal
hypertension have been deﬁned. Within this set of therapies,
preference for one therapy over another is obvious in some groups
and institutions. To date, all types of treatments for portal hyper-
tension have been performed at our institution. The aim of the
present study is to investigate the clinical outcomes of using
selective portosystemic shunting for treating recurrent bleeding GV
in portal hypertensive patients with well-preserved liver function
over the last decade.
2. Materials and methods
Between January 2001 and December 2010, 12 patients under-
went DSRS by hepatobiliary and liver transplantation surgeons at
the Buddhist Tzu-Chi General Hospital in Hualien, Taiwan. Patients
with well-compensated liver function or Child-Turcotte-Pugh classFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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after the failure of endoscopic sclerotherapy. The approval of the
research ethics committee of our institution was obtained for this
retrospective review of the medical records of this cohort of
patients (IRB100-08). Medical records were examined to determine
patient demographics, cause of portal hypertension, documented
variceal type, ChildeTurcotteePugh class of liver cirrhosis, peri-
operative complications, 30-day mortality, late rebleeding (>3
months), and long-term outcomes. Descriptive analyses of the data
were performed using Microsoft Ofﬁce Excel.
2.1. Surgical technique
All patients with preserved liver function underwent elective
DSRS operations following more than one episode of variceal
bleeding, except for one patient who had severe thrombocytopenia.
Preoperative dynamic abdominal computed tomography was
arranged in order to determine that: (1) the splenic vein was of an
adequate diameter without spontaneous portosystemic shunts, (2)
the ascites was fully controlled, and (3) there were no hepatic or
pancreatic lesions. We preferred the use of the Citron incision for
the upper abdominal laparotomy followed by exposure of the
splenic vein via the lesser sac by lifting the pancreas. We dissected
the splenic vein from the level of conﬂuence of the superior
mesenteric and portal vein (SMPV) to the distal pancreas more than
6 cm in length. The inferior mesenteric veinwas ligated if it drained
into the splenic vein. The left renal vein was dissected and exposed
from the avascular window of the transverse mesocolon. The
splenic vein was transected at the level of SMPV for DSRS. We
performed end-to-side anastomosis of the splenic vein and left
renal vein using 4-0 Prolene sutures (Ethicon, Inc.) continuously
with half the diameter of anastomosis as growth factor, as shown in
Fig. 1. Starting in 2006, we performed DSRS with splenopancreatic
disconnection to further maintain the selective shunting.
3. Results
Twelve consecutive patients were recruited, including eight
men, two women, and two pediatric patients. The mean age of
the adults was 49.5 years. Liver function was classiﬁed as
ChildeTurcotteePugh class A in six of the eight patients with
cirrhosis and as class B in the remaining two patients. The two
pediatric patients were diagnosed with idiopathic prehepatic
portal hypertension. Except for one patient with hypersplenism, all
patients had had at least one episode of rebleeding GV after the ﬁrstFig. 1. Distal splenorenal shunt and anastomosis between the proximal splenic vein
and left renal vein.endoscopic treatment, and that in combination with bleeding
esophageal varices (EV) occurred in seven patients. All patients
received the DSRS operation. Starting in 2006, we also performed
splenopancreatic disconnection (7 patients). The median follow-up
period was 53 months (range: 7e115 months). The clinical proﬁles
are shown in Table 1.
There was no 30-day or in-hospital mortality in any of these 12
patients. No hepatic insufﬁciency, shunt occlusion, pancreatic
leakage, pneumonia, acute kidney injury, or wound infection was
identiﬁed during the perioperative period. The perioperative
results are shown in Table 2. Postoperative deterioration of liver
function occured in three of the 12 patients (25%), in terms of
ChildeTurcotteePugh class, but all patients recovered without
additional events.
No clinical symptoms or signs of hepatic encephalopathy
developed in any patients during hospitalization or the follow-up
period. No perioperative rebleeding was noted in this series of
patients, but late rebleeding EV was identiﬁed in two patients. The
ﬁrst patient presented with bleeding EV at 3 months post-
operatively, which further progressed the patient’s portal hyper-
tension following limited proportional portosystemic shunt; this
might have led to rebleeding because of the artiﬁcial conduit
(8-mm polytetraﬂuoroethylene [PTFE] IMPRA CenterFlex Graft, C.
R. BARD, Inc.) that was placed between the splenic and renal vein.
The second pediatric patient developed bleeding EV 3 years post-
operatively because of the relatively inadequate shunting with his
growth. These bleeding varices were conﬁned to the distal esoph-
agus and successfully managed by endoscopic treatments.
Two patients died during the follow-up period. One patient died
from pulmonary malignancy 23 months postoperatively and the
other patient died from pneumonia 45 months postoperatively.
One patient developed hepatocellular carcinoma, underwent local
ablation therapy, and is now listed to receive a liver transplantation.
Two of the 12 patients are presently on the waiting list for liver
transplantation.
4. Discussion
Many randomized controlled trials comparing DSRS with
endoscopic sclerotherapy and/or TIPSS for treating variceal
rebleeding have conﬁrmed the efﬁcacy of DSRS [6e10]. The variceal
rebleeding rate of DSRS has been shown to be <10%, which is
similar to the results of TIPSS and less than endoscopic or phar-
macologic treatments, which is as high as 47% [11]. The efﬁcacy of
pharmacologic treatment for variceal rebleeding, especially of the
GV, is not satisfactory and is restricted by the adverse effects such as
cardiac failure, asthma and symptomatic bradycardia. In our series,
two patients experienced late variceal rebleeding under the status
of shunt patency that was proven by color Doppler ultrasonography
and contrast-enhanced computed tomography. A possible cause is
inadequate portosystemic shunting due to a low hepatic venous
pressure gradient (HVPG). The 8-mm PTFE Gore-Tex graft is the
largest artiﬁcial conduit available at our institution, but this is still
smaller than the splenic and renal vein diameters and can
adequately divert portal blood ﬂow. Portal blood ﬂow is propor-
tional to cardiac output and increases with age and body surface
area. This limited and relative inadequate conduit, in terms of
material and size, might have led to late bleeding in our two
patients. No episodes of variceal rebleeding or variceal enlargement
were noted in the other 10 patients on follow-up with endoscopy.
HVPG measurement is a good way to evaluate therapeutic effects
and predict rebleeding after a shunt operation [12]. Regrettably,
HVPG measurement is an invasive procedure and was not available
at our institution. In reality, HVPGmeasurement is not incorporated
into daily practice at the vast majority of institutions.
Table 1
Patient demographic data and clinical proﬁles.
Pt. No. Age (y) Gender Etiology CTP MELD Surgical Indication Operation Complication Late rebleeding Follow-up (mo)
1 30 M Alcohol B N/A GV rebleeding DSRS No N/A N/A
2 51 M Alcohol A 10 GV rebleeding DSRS No No 115
3 53 F HCV A 10 Hypersplenism DSRS No No 26
4 54 M HBV/HCV A 9 GV rebleeding DSRS No No 94
5 4 M Idiopathic d d GV rebleeding DSRS No Yes 73
6 46 F HBV B 9 GV rebleeding DSRS þ SPD No No 68
7 58 M Idiopathic A 9 GV rebleeding DSRS þ SPD No No 68
8 60 M HCV A 8 GV rebleeding DSRS þ SPD No No 31
9 43 M HBV/Alcohol B 12 GV rebleeding DSRS þ SPD No Yes 46
10 11 M Idiopathic d d GV rebleeding DSRS þ SPD No No 35
11 54 M Pancreatitis d d GV rebleeding DSRS þ SPD No No 25
12 46 M HCV/Alcohol A 11 GV rebleeding DSRS þ SPD No No 7
CTP: Child-Turcotte-Pugh; DSRS: Distal Splenorenal Shunt; EV: Esophageal Varices; GV: Gastric Varices; MELD: Mode for End-Stage Liver Disease; N/A: Not Available;
SPD: Splenopancreatic Disconnection.
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life-threatening complication that can occur after endoscopic
therapy, especially bleeding GV, and can manifest in large varices
with a difﬁcult clinical approach. Compared with DSRS, TIPSS
shows similar results for the prophylaxis of variceal rebleeding, but
leads to a greater risk of encephalopathy and requires frequent
interventions in order to maintain patency [9,11]. TIPSS also has
a 75% incidence of shunt dysfunction or thrombosis within 6
months to 1 year that can be detected by duplex ultrasonography
[13,14]. Helton et al conducted a prospective, randomized trial on
40 patients with ChildePugh class A or B and variceal bleeding; 20
patients underwent DSRS and 20 underwent TIPSS. The patients
who underwent TIPSS demonstrated a higher mortality rate, more
rebleeding episodes, and required more rehospitalization than
those treated with DSRS. In order to avoid TIPSS loss, patients must
undergo frequent surveillance by duplex ultrasonography or
venography and face the risk of percutaneous dilatation or rest-
enting [15]. DSRS has been shown to be more cost-effective than
TIPSS for treating severely compensated cirrhotic patients with
variceal rebleeding [16]. DSRS is also better suited for treating
noncompliant patients and for those with limited access to
specialized medical centers capable of dealing with TIPSS failures
[17]. There are fewer specialized endoscopists in eastern Taiwan
than western Taiwan, and most patients are typically a long
distance from the nearest the tertiary medical center. Hence,
surgical selective portosystemic shunts are the preferred treatment
for treating rebleeding GV in patients with severely compensated
liver function in eastern Taiwan.
The maintenance of portal circulation by splenopancreatic
disconnection plays a role in the development of encephalopathy. A
study by Spina et al found no cases of chronic encephalopathy in
patients who underwent splenopancreatic disconnection [18].Table 2
Perioperative results.
Operation Type
DSRS 5
DSRS þ SPD 7
OP Time (minute) 280 (220-360)
Blood Loss (ml) 267 (50-1100)
Warm ischemic time of left kidney (minute) 24 (17-37)
Length of Hospital Stay (Day) 10.1 (7-17)
Encephalopathy 0
Early Rebleeding 0
Complications 0
Mortality 0
DSRS: distal splenorenal shunt; SPD: splenopancreatic disconnection.There also are several advantages to DSRS over other selective and
nonselective shunts for controlling variceal rebleeding. Selective
decompression of the gastroesophageal varices by splenic circula-
tion maintains portal ﬂow into the liver and the delivery of the
hepatotrophic factors that preserve hepatic function and volume
[19,20]. In our series, no patient developed encephalopathy or
deteriorated liver function during hospitalization or the follow-up
period. The transient change in liver function is based on the
ChildeTurcotteePugh classiﬁcation, but the most severely affected
parameter in three patients was the serum albumin level, which
might have contributed to the development of postoperative
systemic inﬂammatory response syndrome. Moreover, DSRS makes
it possible to avoid dissection and mobilization of the hep-
atoduodenal ligament, which signiﬁcantly complicates liver trans-
plantation [21]. Two patients in this series have been on thewaiting
list for liver transplantation for more than 4 years. According to the
allocation principle and organ shortages in Taiwan, the waiting
time might be more than 5 years for patients with well-
compensated liver cirrhosis who present with complications.5. Conclusions
Because of the current geographic andmedical considerations in
eastern Taiwan, DSRS may be considered the ﬁrst-line therapy for
treating rebleeding GV in patients with ChildeTurcotteePugh class
A and early class B cirrhosis who have failed to improve following
endoscopic treatment and are unlikely to receive liver trans-
plantation within 5 years. The durability of DSRS makes it a much
better option for some patients and also avoids the disadvantages
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